Alemtuzumab: all 222 studies that test it
Page 3 of 3. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic LeukemiaCompletedNCT00102661Phase 2
- Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00089349Phase 2
- Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00086775Phase 2
- Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00085449Phase 1/2
- Alemtuzumab in Treating Patients With Waldenstrom's MacroglobulinemiaWithdrawnNCT00081068Phase 2
- Alemtuzumab to Treat Sporadic Inclusion Body MyositisCompletedNCT00079768Phase 2
- Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHLTerminatedNCT00077961Phase 1/2
- Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00073879Not applicable
- Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CMLTerminatedNCT00069992Phase 2
- Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary SyndromeCompletedNCT00057967Phase 2
- Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell TransplantationCompletedNCT00057005Phase 1
- Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage DiseasesTerminatedNCT00056979Phase 1/2
- Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological DiseasesCompletedNCT00056966Phase 1/2
- Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's LymphomaTerminatedNCT00051701Phase 1/2
- Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1HCompletedNCT00048412Phase 1/2
- Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1HTerminatedNCT00048399Phase 1/2
- Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic LeukemiaCompletedNCT00046683Phase 3
- Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid MalignanciesTerminatedNCT00038883Not applicable
- Safety and Efficacy of Campath in Nonmyeloablative TransplantationCompletedNCT00038844Not applicable
- Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic LeukemiaCompletedNCT00021151Not applicable
- Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00006390Phase 2
- Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00004857Phase 2